Background: We conducted a genomewide association study (GWAS) for maximum number of alcoholic drinks consumed in a 24-hour period ("MaxDrinks"), in 2 independent samples comprised of over 9,500 subjects, following up on our GWAS for alcohol dependence (AD) in European Americans (EAs) and African Americans (AAs).
A LCOHOL CONSUMPTION IS a moderately heritable phenotype, with heritability estimated at approximately 0.5 . Quantitative measures of the heaviness of alcohol consumption have greater power for gene discovery than dichotomous measures of alcohol phenotypes, such as alcohol dependence (AD), as they better represent the underlying continuum of alcohol-related problems. The maximum number of alcoholic drinks consumed in a 24-hour period (MaxDrinks) is a quantitative measure that can be considered an intermediate phenotype or a proxy for AD for gene detection; Diagnostic and Statistical Manual of Mental Disorders (DSM) criterion count is another such measure Kendler et al., 2010; Quillen et al., 2014; Wang et al., 2013) . Although MaxDrinks is highly correlated with AD, MaxDrinks is directly associated with alcohol metabolism and physiopathology, which AD is a more heterogeneous diagnosis including social functions and legal problems. Genes identified for MaxDrinks may more likely be biologically relevant to alcohol consumption.
Previous linkage studies have located genetic variants associated with MaxDrinks on chromosomes 2, 4, and 7 in European Americans (EAs) (Saccone et al., 2000 (Saccone et al., , 2005 , and chromosomes 12 and 18 in a study of Irish affected sibpairs (Kuo et al., 2006) . Consistent with gene-based association studies for AD, the strongest and most consistent signals for MaxDrinks in European-ancestry populations are located on ADH1B, a gene that encodes an alcohol dehydrogenase, a key enzyme in alcohol metabolism (Bierut et al., 2010; Macgregor et al., 2009) . A functional single nucleotide polymorphism (SNP) at ADH1B, rs1229984 (A>G Arg48His), has been associated with MaxDrinks in Asian, Israeli, Australian, and EA populations (Bierut et al., 2012; Macgregor et al., 2009; Meyers et al., 2015) , with the His48 allele conferring a protective effect against heavy consumption (i.e., lower MaxDrinks). This variant is uncommon in individuals of African descent and has not been found to be associated with MaxDrinks in African American (AA) samples; however, rs2066702 is another functional variant with similar functional effects associated with AD diagnostic traits in AA samples . Gene-based studies have reported an association between rs671 at ALDH2 and reduced MaxDrinks in Asian populations, but not in EAs or AAs, where this variant is uninformative. Our recent genomewide association study (GWAS) in a relatively isolated Chinese population confirmed this locus on ALDH2 for MaxDrinks that explained 22.9% of the phenotypic variation in our sample (Quillen et al., 2014) .
Although several GWAS, including our recent study in EAs and AAs, identified risk loci for AD (Gelernter et al., 2014a; Park et al., 2013; Schumann et al., 2011; Treutlein et al., 2009) , GWAS for the "MaxDrinks" trait have not yielded robust associations in EAs or AAs Kapoor et al., 2013; Pan et al., 2013) . A nominally significant association (rs9512637 on chromosome 13, p = 1.2 9 10 À7 ) for a heaviness of alcohol drinking factor score was found in a large Australian twin population , in which the SNP density was relatively low. Several recent meta-analyses from large consortium samples (the Collaborative Study on the Genetics of Alcoholism [COGA] and the Study of Addiction: Genes and Environment [SAGE] ) revealed no genomewide significant markers for this phenotype Pan et al., 2013) . However, multiple loci approached significance, including SNPs at LMO1, PLCL1, KCNB2, and DDC Pan et al., 2013) . One study identified a locus on C12orf51 associated with alcohol consumption in Korean men at an extremely high level of significance (p = 5.8 9 10 À46 ) (Baik et al., 2011) . Interestingly, the majority of these GWAS have not replicated the association of the ADH1B gene with MaxDrinks that was previously reported from several studies (Bierut et al., 2012; Macgregor et al., 2009 ) except for one (2.04 9 10 À8 ) in the combination of COGA and SAGE samples . Thus, in order to identify genetic influences on MaxDrinks and to establish the role of ADH1B on MaxDrinks, additional GWAS in large sample populations with high-density genotyping arrays in EAs and AAs are warranted.
Here we report a GWAS with MaxDrinks in our EA and AA samples and the publicly available (via dbGAP application) SAGE data set. We combined sample sets through meta-analysis, yielding a total sample of more than 9,500 subjects. This is the largest GWAS for MaxDrinks to date and is particularly noteworthy for its large AA representation.
MATERIALS AND METHODS

Subject Characteristics
The study samples included our GWAS samples (Yale-UPenn) (N = 5,543) and the public samples (SAGE: phs000092.v1.p1, N = 4,012). Sample characteristics are shown in Table 1 . The YaleUPenn sample was recruited for studies of the genetics of drug (opioid or cocaine) or AD. The SAGE sample consists of the COGA (Edenberg, 2002; , the Family Study of Cocaine Dependence (Grucza et al., 2008) , and the Collaborative Genetic Study of Nicotine Dependence (Bierut, 2007) samples. We obtained the SAGE data via dbGAP.
The Yale-UPenn Sample. Detailed descriptions of recruitment and assessment procedures from this multi-site study can be found in previous publications (Gelernter et al., 2014a,b) . The sample consisted of small nuclear families originally collected for linkage studies and unrelated individuals. Briefly, subjects were interviewed using the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA) to assess symptoms of drug use and other major psychiatric disorders Pierucci-Lagha et al., 2005) . MaxDrinks was assessed with the question "In your lifetime, what is the largest number of drinks you have ever had in a 24-hour period, including all types of alcohol?" The number of drinks was coded as standard drinks. We used log-transformed MaxDrinks (LogM) values to represent MaxDrinks in the analysis models. A total of 2,328 EA and 3,215 AA subjects had MaxDrinks data. The mean of LogM was 2.95 AE 0.84 in the EA sample and 2.57 AE 1.01 in the AA samples. The LogM in AAs was significantly lower than in EAs (p < 0.0001). The distributions of LogM for EA and AA samples are shown in Fig. S1 .
The SAGE Sample. SAGE is funded as part of the Gene Environment Association Studies initiative supported by the National Human Genome Research Institute (http://www.ncbi.nim.nih.gov/ projects/gap/cgi-bin/study.cgi?study_id=phs000092.v1.p1). A total of 2,736 EA and 1,276 AA unrelated individuals were included for this study. Some cocaine users were recruited for SAGE, and the sample informative for alcohol MaxDrinks was also partially comorbid with cocaine use. SAGE also included the individuals with Fagerstrom test for nicotine dependence >3. Alcohol and nicotine dependence are common in population. We did not exclude subjects with nicotine dependence. The number of MaxDrinks was assessed by inquiring as to the number of standard drinks consumed within a 24-hour period. Consistent with the MaxDrinks variable from YaleUPenn, the MaxDrinks reported in the SAGE data were transformed to LogM for genetic analysis. A detailed description of this sample was reported previously (Gelernter et al., 2014a; Wang et al., 2013) . 
Genotyping and Quality Control
The Yale-UPenn samples were genotyped using the Illumina HumanOmnil-Quad v1.0 microarray (Illumina, San Diego, CA) containing 988,306 autosomal SNPs, at the Center for Inherited Disease Research and the Yale Center for Genome Analysis. Genotypes were called using Illumina GenomeStudio software V2011.1 and genotyping module V 1.8.4. The SAGE samples were genotyped on the Illumina Human 1M array containing 1,069,796 total SNPs. We used the following criteria for genotyping quality control filtering: (i) call rate >98%; (ii) minor allele frequency (MAF) >1%; and p-value for Hardy-Weinberg Equilibrium >5 9 10
À6
. After data cleaning, 44,644 SNPs on the microarray and 135 individuals with call rates <98% were excluded; 62,076 additional SNPs were removed due to MAF <1%. After data cleaning and quality control, 5,543 individuals and 889,659 SNPs remained for the imputation. After applying the same quality control procedures to the SAGE sample, 39 subjects with call rates <98% were excluded. Thus, in the SAGE sample, 4,012 individuals and 726,191 SNPs remained for analysis.
In addition, we examined the genetic relationships in the familybased samples for the Yale-UPenn samples by estimating pairwise identity by descent (IBD) proportion using PLINK v1.90a (http:// pngu.mgh.harvard.edu/~purcell/plink/). Individuals who shared more than 25% of their alleles IBD were assigned to the same family.
Genotyping Imputation. We used the 1000 Genomes data set (http://www.1000genomes.org/) as a reference to impute genotyping for our Yale-UPenn and SAGE samples. The program IMPUTE2 was applied for genotyping imputation (https://mathgen.stats.ox.a c.uk/impute/impute_v2.html#home). EA and AA populations were imputed separately within each data set.
Statistical Analysis
Population Stratification. We conducted principal component (PC) analysis to address population structure in the Yale-UPenn samples and SAGE samples using the program Eigensoft Price et al., 2006) . SNPs were pruned for linkage disequilibrium estimated by r 2 > 0.8. The first PC score distinguished AAs and EAs. Thus, we analyzed AAs and EAs separately to minimize population admixture. Within each population, the top 3 PCs were then used in all analyses to correct for residual population stratification.
Association Analysis. A linear association model was applied for association analyses between SNPs genomewide for the LogM. In this analysis, MaxDrinks was the dependent variable and each SNP was a predictor. Each model was adjusted for age, sex, and the first 3 ancestry PCs. Consider body weight may influence alcohol distribution and consumption, we conducted a separate analysis with body mass index (BMI) as an additional covariate. The p-value for genomewide significance was set at 5.0 9 10
À8
. To further limit the confounding factors, we tested models for moderately associated SNPs (p < 1 9 10 À4 ) for dependence on cocaine, opioids, and alcohol-3 major comorbid substance use in our samples.
Meta-Analysis of the Yale-UPenn and SAGE Samples. We used the program METAL to meta-analyze the combined results of the Yale-UPenn and SAGE samples (Willer et al., 2010) . Inverse variance was applied to the analysis.
Conditional Association Analysis. To identify additional association signals after accounting for the known loci, we ran conditional analyses, in which we included the significant allele counts at the conditioning loci as covariates to calculate conditional p-values for EAs and AAs. We adjusted for the effect of rs1229984 in the EA samples and for rs2066702 in the AA samples-the 2-peak significant SNPs in those populations.
RESULTS
Genomewide Association
We identified multiple significant loci on chromosome 4 for MaxDrinks in both EA and AA populations (Figs 1-3) . Within a 236-kb region on chromosome 4, 1 SNP was significantly associated with MaxDrinks in EAs, and 8 SNPs were significantly associated in AAs (Table 2) . Three of the 9 SNPs were uniquely associated with MaxDrinks; the other 6 were also strongly associated with AD in our previous study (Gelernter et al., 2014a) . In this study, the significant signals were mostly driven by the Yale-UPenn sample.
The peak GWAS hits were from the ADH1B locus. As expected, the functional SNP rs1229984 (A>G Arg48His) showed the strongest association with MaxDrinks in the EAs from combined Yale-UPenn and SAGE samples (MAF = 0.06, p = 5.96 9 10 À15 , b = À0.26) ( Table 2 , Fig. 1A,B ). This SNP remained highly significant after adjusting for BMI (p = 4.27 9 10 À12 ). Individuals with His48 allele reported less number of maximum drinks within 24 hours than homozygote Arg48 individuals (Fig. 4A ). This SNP is minimally informative in AA samples. However, another functional SNP in ADH1B, rs2066702, was strongly associated with MaxDrinks in the AAs from the combination of Yale-UPenn and SAGE samples (MAF = 0.19, p = 2.5 9 10 À10 , b = À0.16, p = 1.89 9 10 À8 adjusting for BMI) ( Fig. 2A,B) . Individuals carrying Cys allele reported less number of maximum drinks (Fig. 4B) . Two other SNPs in ADH1B, 1 synonymous SNP, rs1789882 (Ile251Ile) (MAF = 0.23, p = 2.10 9 10 À9 , b = À0.14), and 1 intronic SNP, rs1693457 (MAF = 0.23; p = 4.24 9 10 À9 , b = À0.14), were significant in AAs but were monomorphic in EAs. All 4 SNPs in ADH1B were previously shown to be significantly associated with AD. These findings confirm the contribution of ADH1B to the development of alcoholrelated pathophysiological phenotypes. Our prior GWAS used AD criteria and diagnosis as traits; however, MaxDrinks is not among the AD diagnostic criteria. Regional Manhattan plots on chromosome 4 close to ADH cluster are showed in Fig. 3A for EAs and in Fig. 3B for AAs.
Consistent with our previous findings for AD on chromosome 4, the region that was associated with MaxDrinks also extended to the locus LOC100507053. Five SNPs at LOC100507053, which is in the same genomic region as the ADH cluster, were significant only in the AA sample (Fig. 3B ). This uncharacterized RNA gene was previously associated with AD symptom count (Gelernter et al., 2014a) . Three of these 5 significant SNPs were associated in this study but were not observed in our previous AD GWAS. We also previously found that 11 SNPs in ADH1C were associated with AD symptom count (Gelernter et al., 2014a) . None of those SNPs were associated with MaxDrinks, although there was 1 marginally significant SNP in the AA population in the combined Yale-UPenn and SAGE samples (rs34009511, p = 8.11 9 10 À8 ).
In addition to the genomic region on chromosome 4q, we identified 2 significant loci for EAs. In the EA samples, rs1799876 on chromosome 1 and rs2309169 on chromosome 2 showed significant association (rs1799876: MAF = 0.38, p = 4.00 9 10 À8 , b = À0.16; rs2309169, p = 5.58 9 10 À9 , b = À0.28) (Fig. S2A,B) . Rs1799876 maps to SERPINC1, which encodes a plasma protease inhibitor. Rs2309169 is located 10 kb downstream to Ankyrin Repeat Domain 36 (ANKRD36). In AAs, a SNP rs1140833 SMPD1 on chromosome 11 showed significant association with MaxDrinks, which was mostly driven by the SAGE sample (p = 1.10 9 10 À8 ). However, this locus was not significantly associated in neither our AA samples nor in the meta-analysis in the combination samples, and the effects of the SNP were opposite direction in the SAGE sample and the combined sample, suggesting a potential spurious significant SNP.
Conditional Analysis
To evaluate whether identified SNPs contribute independently to MaxDrinks, we repeated the analyses, conditioning on the most significant ADH1B SNPs in each population: rs1229984 in EAs and rs2066702 in AAs. In EAs, after adjusting for rs1229984, rs2309169 on chromosome 2 remained highly significant (p = 2.12 9 10
À9
) and rs1799876 ). Two novel loci were rs1799876 on chromosome 1 (p = 4.00 9 10
À8
) and rs2309169 on chromosome 2 (5.58 9 10 À9 ). After adjusting for rs122984 on ADH1B, rs2309169 remained significant (p = 2.12 9 10 À9 ), but rs1799876 was nearly significant (p = 1.99 9 10 À7 ).
on chromosome 1 was nearly significant (p = 1.99 9 10 À7 ). In AAs, after adjusting for rs2066702, among the 8 SNPs identified as significant in the combined Yale-UPenn and the SAGE samples, only 1 SNP remained significant. Rs200475889 on chromosome 4 showed significant association in the Yale-UPenn AAs after adjusting for rs2066702 (p = 4.80 9 10 À8 ), suggesting that both of these SNPs contributed to genetic risk for MaxDrinks in this population.
Thus, independent loci other than ADH1B contributed to MaxDrinks in both AAs and EAs.
DISCUSSION
We identified multiple significant loci for peak daily alcohol consumption (MaxDrinks) in a large sample of EAs and AAs, thus expanding the existing literature in several ways. a: Not tested because of low MAF or poor imputation quality. Highlighted as red SNPs were identified associations for alcohol dependence in our previous study (Gelernter et al., 2014a) .
Bold numbers are genomewide significance.
First, the association of the functional ADH1B SNP rs1229984 with MaxDrinks in EAs is consistent with previous observations. This finding provides additional support for a role of that locus in determining alcohol consumption, as well as increasing confidence in our findings implicating other loci relevant to drinking behavior. Second, this is the first report of a significant association of rs2066702 at ADH1B with MaxDrinks in an AA population-this finding is not unexpected, as it is similar to the finding in EAs. Third, additional protective loci, that is, alleles mapped to genes not previously associated with either MaxDrinks or AD, were identified in both EA and AA populations. It is also noteworthy that the significant genes or alleles associated with MaxDrinks were population specific (in all cases except ADH1B), suggesting that different genes and perhaps different biological pathways may be involved in this trait in different populations. This pattern of findings also reinforces the importance of stratifying populations for gene discovery when using a GWAS approach. The ADH1B gene has been previously associated with MaxDrinks and related alcohol phenotypes in EA populations using linkage and candidate gene approaches. A genome scan of MaxDrinks identified significant loci in the 4q21.3 region (the maximal logarithm of odds = 3.5), a region to which the ADH gene cluster maps. Drinkers with the ADH1B rs1229984*Arg48 allele were less likely to have a flushing response to alcohol (Bierut et al., 2012; Chen et al., 1999) , report a higher MaxDrinks count (Bierut et al., 2012; Macgregor et al., 2009) , and greater past year alcohol consumption (Edenberg, 2007; Macgregor et al., 2009 ) than those with the rs1229984*His48 allele. Consistent with earlier studies (Bierut et al., 2012) , the genomewide significance of rs1229984 in the current study was 10 À15 in EAs, reflecting a relatively large effect size (b = À0.25). The individuals with His48 allele reported less MaxDrinks in EA population from our Yale-UPenn samples (Fig. 4) . Rs2066702, also at ADH1B, has not previously been associated with MaxDrinks, likely because of its low frequency in EAs and Asians, who are most heavily represented in studies of ADH1B variants and alcohol phenotypes. This SNP has a higher MAF in populations of African descent (0.19 in the present study). The p-value was 10 À10 in the AA population in the combined YaleUPenn and SAGE samples. Rs2066702 (Arg370Cys) is located in exon 9 and encodes the b3 subunit of ADH1B. The substitution of the cysteine residue, which results in more rapid alcohol metabolism than the common arginine residue, was associated with lower MaxDrinks. This finding is consistent with the substitution causing higher levels of acetaldehyde, which are aversive. In addition to the 2 known functional SNPs in ADH1B, rs200475889 was also associated with MaxDrinks, independent of the effect of rs2066702 in the AA samples. These findings, along with our previous findings of significant association of ALDH2 with MaxDrinks in a Chinese population (Quillen et al., 2014) , provide additional strong evidence of a convergent biological pathway that involves alcohol metabolism in different populations.
Beyond the ADH cluster, we identified 2 potential novel loci for MaxDrinks in the EA population. Rs1799876 at SERPINC1 on chromosome 1 was significantly associated with MaxDrinks in our Yale-UPenn EA sample (p = 4.0 9 10 À8 ). It became nearly significant after adjusting for rs1229984 (p = 1.99 9 10 À7 ). SERPINC1, serpin peptidase inhibitor, clade C gene has been associated with thrombosis-related phenotypes (Fischer et al., 2013) . Rs2309169 < 5 -< = 1 0 ( n = 2 6 9 ) < 1 0 -< = 1 5 ( n = 3 2 7 ) < 1 5 -< = 2 0 ( n = 3 1 7 ) < 2 0 -< = 2 5 ( n = 4 3 4 ) < 2 5 -< = 3 0 ( n = 2 1 3 ) < 3 0 -< = 3 5 ( n = 5 2 ) < 3 5 -< = 4 0 ( n = 1 2 8 ) < 4 0 -< = 4 5 ( n = 3 5 ) > 4 5 ( n = 3 0 2 ) < 1 -< = 5 ( n = 1 7 8 ) < 5 -< = 1 0 ( n = 2 7 5 ) < 1 0 -< = 1 5 ( n = 3 2 7 ) < 1 5 -< = 2 0 ( n = 3 2 7 ) < 2 0 -< = 2 5 ( n = 4 4 1 ) < 2 5 -< = 3 0 ( n = 2 2 2 ) < 3 0 -< = 3 5 ( n = 5 3 ) < 3 5 -< = 4 0 ( n = 1 3 3 ) < 4 0 -< = 4 5 ( n = 3 5 ) > 4 5 ( n = 3 1 0 ) B Fig. 4 . The distribution of number of maximum drinks within 24 hours by 2-peak significant single nucleotide polymorphisms. (A) Rs1229984 in European Americans; (B) Rs2066702 in African Americans. The number of drinks was binned by 5 drinks. The number of drinks >45 was combined into 1 group. on chromosome 2 was significantly associated with MaxDrinks in the Yale-UPenn EA samples (p = 5.58 9 10 À9 ). It remained highly significant after adjusting rs1229984 (p = 2.12 9 10
À9
). This SNP is close to ANKRD36. The link of ANKRD36 with MaxDrinks is still unknown.
We previously found a significant association of ALDH2 with MaxDrinks in a Chinese population (Quillen et al., 2014) . No such relationship was observed in either population in the present study, which is not surprising as the allele that is protective in some Asian populations is not observed in either AAs or EAs.
Two other GWAS of alcohol consumption phenotypes have been reported in European-ancestry populations. Heath and colleagues (2011) conducted a GWAS analysis with a well-characterized quantitative phenotype for heaviness of alcohol consumption that included MaxDrinks in the Australian Twin Registry sample (a total of 8,300 subjects), and failed to identify a genomewide significant association . Our success in identifying potential novel loci for MaxDrinks is likely due to a higher density genotyping array and a greater proportion of affected subjects in the present study. Approximately 890,000 SNPs were genotyped in our samples compared to only 30K SNPs in Heath and colleagues' (2011) study. More recently, Pan and colleagues (2013) reported several SNPs at DDC that were associated with MaxDrinks in the SAGE sample (p = 2.87 9 10 À5 ). They also reported an association of rs1128951 on chromosome 3 with MaxDrinks in the combined SAGE and COGA samples (p = 4.3 9 10 À8 ). We did not replicate either finding. The SAGE sample is composed of both EA and AA populations and Pan and colleagues (2013) selected only EA samples in the study. Within each population, we adjusted 3 ancestry PCs to address residual population admixture and Pan and colleagues' study (2013) did not. As discussed above, risk loci for MaxDrinks may differ across populations. Thus, potential population admixture may contribute to inconsistent findings.
The present loci identified via GWAS for MaxDrinks overlap partially with loci identified in our previous GWAS for AD, but independent loci were also observed in each study. These findings suggest that shared genetic influences on MaxDrinks and AD phenotypes are attributable in large part to alcohol metabolism genes. These results are consistent with prior genetic epidemiologic findings from a twin study of alcohol consumption phenotypes, where a high degree of genetic overlap between the heaviness of consumption and AD symptoms was observed ). In our Yale-UPenn sample, significant correlation of MaxDrinks and AD symptoms were also observed in both EAs and AAs (Sartor et al., 2014) . Numerous genes that were reported genomewide significant in GWAS for AD (Gelernter et al., 2014a) , including PDL1M5 in EAs, METAP in AAs, MTIF2 and CCDC88A in both EAs and AAs, were not associated with MaxDrinks in the current study. Similarly, several of the genes associated with MaxDrinks in this study have not been reported previously to be associated with AD, suggesting specific genetic loci contribution to MaxDrinks.
Despite the strengths of the study, certain limitations should be noted. Some of our Yale-UPenn sample was recruited for studies of drug dependence rather than AD, while the SAGE sample was primarily recruited for AD. Although we adjusted for these comorbidities, greater substance dependence comorbidity in the Yale-UPenn sample may have contributed to the differences in findings with respect to the SAGE sample. We note that many prior studies have not taken note of substance use comorbidity at all, and the assumption that there is less comorbidity in those cases where it is not reported, is not necessarily warranted. We also acknowledged the proportion of sex and races are slightly different between 2 data sets. In the meta-analysis, we analyzed associations separately in EAs and AAs, and adjusted sex and other demographics.
Nevertheless, this is among the first study to apply GWAS in a large independent sample for MaxDrinks that included both EA and AA populations. The replication of findings related to the ADH1B validates the analytic strategies. Efforts to replicate the newly identified loci in independent samples are warranted.
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